Three courses of high dose therapy. Feasibility in the treatment of multiple myeloma–a “France autogreffe” study

Abstract

Background. High dose melphalan is used widely in the treatment of multiple myeloma (MM) and in the conditioning regimen of autologous stem cell transplantation (ABST). Double courses of high dose melphalan and double autologous bone marrow transplantation (ABMT) programs also have been widely reported. However, there are no data about the feasibility and efficacy of three courses of high dose therapy, such as high dose melphalan or powerful therapies in the treatment of malignant disease. Methods. In 1991, a retrospective study in France was inititated to evaluate how many patients with MM had received three courses of high dose therapy with or without hematopoietic stem cell rescue. Results. This small study of six patients with multiple myeloma showed that three courses of high dose therapy with or without stem cell rescue can be performed with relative safety. Stem cell rescue appears to shorten the duration of aplasia. In terms of antitumor response, long term response could be obtained in patients with MM that responded to the first course of high dose melphalan. Conclusions. High dose therapy with or without ABMT can be an effective treatment for relapse in a subgroup of patients with MM who respond to high dose melphalan as initial treatment. Copyright © 1994 American Cancer Society